Simponi Aria® Approved for Psoriatic Arthritis In Children 2 Years of Age and Older
This article represents the opinions, thoughts, and experiences of the author; none of this content has been paid for by any advertiser. The Psoriatic-Arthritis.com team does not recommend or endorse any products or treatments discussed herein. Learn more about how we maintain editorial integrity here.
- Simponi Aria (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older. FirstWord Pharma. Available at https://www.firstwordpharma.com/node/1761532. Accessed 10/5/2020.
- Simponi Aria. DailyMed. Available at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9e260a47-55af-4c92-8d88-a86ccc767fff. Accessed 10/5/2020.
- Psoriatic Arthritis in Children. Children’s Hospital of Philadelphia. Available at https://www.chop.edu/conditions-diseases/psoriatic-arthritis-children. Accessed 10/5/2020.
- Oberle EJ, Harris JG, Verbsky JW. Polyarticular juvenile idiopathic arthritis - epidemiology and management approaches. Clin Epidemiol. 2014;6:379-393. doi:10.2147/CLEP.S53168.